Case series reports allodynia (pain from light touch) and dysesthesia (abnormal sensations) associated with semaglutide and tirzepatide use, identifying a previously unreported neurological side effect.
New side effect identifiedAllodynia (touch pain) and dysesthesia (abnormal sensations) reported with semaglutide and tirzepatide — a previously unrecognized neurological effect
What the researchers found
Allodynia and dysesthesia identified as previously unreported neurological side effects of semaglutide and tirzepatide, likely related to GLP-1/GIP receptor effects on sensory neurons.
Why it matters
Millions of people take these drugs. Identifying new neurological side effects — even uncommon ones — is critical for patient safety and informed prescribing.
The numbers in context
Previously reported with semaglutide; this report adds the first tirzepatide case. Both drugs are commonly prescribed for T2DM and weight management.
How the study worked
Case series documenting allodynia and dysesthesia in patients receiving semaglutide or tirzepatide. Clinical presentation, temporal association, and potential mechanisms described.
Who was studied
Individual patients developing allodynia/dysesthesia on semaglutide and tirzepatide
What this study cannot tell us
Case series cannot prove causation. Allodynia and dysesthesia have many possible causes. The symptoms may be coincidental or related to other medications, weight loss, or underlying conditions.
How to read the evidence
Preliminary evidence: case series identifying a new safety signal. Incidence and causation need confirmation in larger studies.
When this study was published
Published in 2025. Important new pharmacovigilance signal for widely used GLP-1/GIP drugs.
The bigger picture
As GLP-1 drugs are used by more people for longer periods, rare side effects will emerge. Neurological symptoms like allodynia suggest these drugs have broader effects on the nervous system than initially appreciated — consistent with GLP-1 receptor expression throughout the nervous system.
Questions still open
- What is the incidence of allodynia/dysesthesia with GLP-1 drugs in larger datasets?
- Are the symptoms reversible upon drug discontinuation?
- Does the mechanism involve direct GLP-1R activation on sensory neurons or indirect metabolic changes?
Common questions
Can semaglutide cause pain or tingling?
Should I stop my GLP-1 drug if I get tingling?
Read the original research
Allodynia and Dysesthesia Associated With Semaglutide and Tirzepatide.
Cureus, 17(10), e94126
Citation
Ahern, Susan. (2025). Allodynia and Dysesthesia Associated With Semaglutide and Tirzepatide.. Cureus, 17(10), e94126. https://doi.org/10.7759/cureus.94126